




## Curriculum Vitae

Personal Information	
Title	Professor
Name	Rupert Leong
Degree	MBBS, FRACP, MD, AGAF
Country	Australia
Affiliation	Director of Endoscopy, Head of IBD Services Concord Hospital, Professor of Medicine University of Sydney, Sydney, Australia
E-mail	RUPERTLEONG(at)HOTMAIL.COM
	
Educational Background	
<p>Rupert Leong graduated from the University of Western Australia School of Medicine and completed FRACP training in gastroenterology and clinical immunology in 2000. He was awarded the Amy and Athelstan Saw Research Fellowship to complete 2 years of training at CUHK, Hong Kong. Upon return to Sydney, he was awarded the prestigious NHMRC Career Development Fellowship.</p>	
Professional Career	
<p>Professor Rupert Leong serves as the Director of Endoscopy and Head of IBD Services at Concord Hospital, in addition to being a Professor of Medicine at both the University of Sydney and Macquarie University in Australia. Prof. Leong is also the founding Director of IBD Sydney and IBD School. He is recognized as the senior author of consensus clinical practice guidelines at both national and international levels. Rupert Leong chairs the Medical Advisory Council at Central Sydney Private Hospital and is associate editor for Therapeutic Advances in Gastroenterology and on the international editorial boards of Alimentary Pharmacology and Therapeutics as well as Gastrointestinal Endoscopy. Prof. Leong is frequently sought after for his expertise, offering insights on medication submissions and advice on funding policies to influential bodies such as the Pharmaceutical Benefits Advisory Council of Australia and the Pharmaceutical &amp; Technology Clinical Management Association of South Africa.</p>	
Research Field	
<p>Crohn's disease, ulcerative colitis                      Endoscopy, advanced imaging technologies, intestinal permeability                      Intestinal microbiome, faecal microbiota transplantation                      Quantitative research – quality of life, disability                      Pregnancy and IBD</p>	
Main Scientific Publications	
<ol style="list-style-type: none"> <li>Chetwood JD, ... Leong RW, Kaakoush NO. Key metabolomic alterations are associated with ulcerative colitis disease state and activity: a validation analysis. <i>Gut</i>. 2023 Aug 17.</li> <li>Anderson E, ... Leong RW. Adalimumab originator versus adalimumab biosimilars in inflammatory bowel disease in Australia. <i>Expert Opin Biol Ther</i>. 2023 Jul-Dec;23(8):819-825.</li> <li>Laube R, ... Leong RW. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. <i>Gut</i>. 2023 Jun;72(6):1040-1053.</li> <li>Hocking L, Ianiro G, Leong RW, ... Faecal microbiota transplantation for recurrent <i>C. difficile</i> infections: challenges and improvement opportunities for clinical practice and healthcare systems. <i>Aliment Pharmacol Ther</i>. 2023 Mar;57(5):549-564.</li> <li>Haifer C, ... Leong RW. Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial. <i>Lancet Gastroenterol Hepatol</i>. 2022 Feb;7(2):141-151.</li> <li>Haifer C, ..., Leong RW, Kaakoush NO. Microbial determinants of effective donors in faecal microbiota transplantation for UC. <i>Gut</i> 2022 Jul 25;gutjnl-2022-327742.</li> <li>Pudipeddi A, ..., Leong RW. Vedolizumab has longer persistence than infliximab as a first-line biological agent but not as a second-line biological agent in moderate-to-severe ulcerative colitis: real-world registry data from the</li> </ol>	



Persistence Australian National IBD Cohort (PANIC) study. *Therap Adv Gastroenterol.* 2022 Mar 8;15:17562848221080793.

8. Laube R, ..., Leong RW. Assisted Reproductive Technology in Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis. *Am J Gastroenterol.* 2021 Dec 1;116(12):2334-2344.
9. Ko Y, ..., Leong RW. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. *Aliment Pharmacol Ther.* 2021;54(3):292-301
10. Pudipeddi A, ..., Leong R. High prevalence of Crohn disease and ulcerative colitis among older people in Sydney. *Med J Aust.* 2021;214(8):365-370